Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Richard Greil, Marija Balić et al.|Nature Cancer|2025Cited by 10
HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXdChristian F. Singer, Stephan Jahn, Dominik Hlauschek et al.|癌症：英文版|2025Cited by 3
123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE)Gabriel Rinnerthaler, Richard Greil, Daniel Egle et al.|ESMO Open|2023Cited by 2